Monday, 19 January 2015

ClinicSpeak: keeping up-to-date with the natalizumab PML risk

Moving PML risk communication from paper to a digital format: what do you think? #ClinicSpeak #MSBlog #MSResearch 

"I am aware that many people come to our blog to keep up-to-date with the latest natalizumab PML-risk figures. We created a simple downloadable infographic that explains things in a simple way; despite this document being viewed 1.3 million times it is not easy to view on a mobile phone therefore we have created a simple APP to the job. In fact, it is not an APP  but a website that is designed using HTML5 that makes it work across platforms (iOS, Android, Windows, Linux, Chrome, etc.). We would appreciate it if you could look at both the paper version and the APP and see which one you prefer and then score them using our quick survey below. Many thanks."


Paper vs. App?




CoI: multiple

2 comments:

  1. If my titre level is 0.3 and I have been on Tysabri for 6 months. My two questions are:
    1. Should I check my titre level every so often? If yes, how frequent?
    2. How frequent should I take a MRI?
    3. Is there a significant difference between 0.3 and 0.9?
    4. Is it possible to move from positive to negative JCV?
    5. When comparing to other drugs for other diseases, or even comparing to other diseases itself...1/3333 on Tysabri TO dying from cancer; how more likely would we take that risk...

    I look forward to hearing from you

    ReplyDelete
  2. if my titre level is 2.6 and have been on tysabri for 7 years my question is this
    1. being told i have 1 in 70 chance of pml get off a.s.a.p.
    2. how does a person make a life changing decision when not enough research has been done on a jc positive switching from tysabri to gilenya?
    please give me some feedback

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.